Laplace Interventional secures $22M in Series C financing to advance its transcatheter tricuspid valve technology, aiming to improve treatment for Tricuspid Regurgitation (TR) patients globally.
 |
| Laplace Interventional completes $22M Series C funding round to progress its innovative tricuspid valve device, with participation from Aphelion Capital and other strategic investors. Image: Symbolic |
Minneapolis, USA — March 16, 2025:
Laplace Interventional, a Minnesota-based medical device company, has raised $22 million in Series C financing to advance its innovative transcatheter tricuspid valve technology. The funding round, led by a global strategic investor, also saw contributions from Aphelion Cardeation, Unorthodox Ventures, Engage Venture Partners, JWC Venture, and Features Capital. The company also announced the addition of Ned Scheetz, Founding Managing Partner of Aphelion Capital, to its Board of Directors.
The funds will support the completion of Laplace's Early Feasibility Study (EFS) and progress toward a pivotal trial for its prosthetic valve, designed to treat Tricuspid Regurgitation (TR). This condition affects millions of patients globally, and Laplace's device offers a minimally invasive alternative to open-heart surgery, potentially reducing complications and improving patient outcomes.
Dr. Brandon Jones, Interventional Cardiologist and Medical Director of Structural Heart at Providence St. Vincent Medical Center in Portland, Oregon, praised the system's ease of use and effectiveness, sharing positive outcomes from the company’s initial patient treatments. Laplace has enrolled 22 patients in the U.S. as part of its EFS, with global participation reaching 25 patients, showing encouraging results.
Ramji Iyer, PhD, CEO of Laplace Interventional, expressed gratitude for the support from investors and medical professionals, emphasizing the company’s commitment to transforming TR treatment. “This round of financing marks a significant milestone and further validates our progress,” said Iyer.
Ned Scheetz of Aphelion Capital commended Laplace’s innovative approach and its potential to transform TR care on a global scale. “We are proud to support this breakthrough technology, which aligns with the mission of the American Heart Association,” said Scheetz.
It’s important to note that Laplace Interventional's device is currently in the development phase and has not yet been approved by the FDA or other regulatory bodies.